|
EMA: initial marketing authorisation for vismodegib for the treatment of BCC |
|
Written by AlexandraBartal
|
|
Monday, 17 June 2013 11:23
|
|
|
|
|
|
Read more...
|
|
|
EMA: initial marketing authorisation for enzalutamid 40 mg intended for the treatment of mCRPC |
|
Written by AlexandraBartal
|
|
Sunday, 16 June 2013 11:18
|
|
|
|
Read more...
|
|
EMA: marketing authorisation of lipegfilgrastim for prophylaxis against CHT-induced neutropenia |
|
Written by Alexandra Bartal
|
|
Saturday, 15 June 2013 11:07
|
|
|
|
|
|
Read more...
|
|
